{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:40:53Z","timestamp":1779334853479,"version":"3.51.4"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.jaad.2015.01.002","type":"journal-article","created":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T00:03:09Z","timestamp":1421798589000},"page":"703-711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Review of thalidomide use in the pediatric population"],"prefix":"10.1016","volume":"72","author":[{"given":"Catherine S.","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changhyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Antaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2015.01.002_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/00002018-200124020-00002","article-title":"Thalomid (thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing","volume":"24","author":"Clark","year":"2001","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2015.01.002_bib2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2133.2005.06747.x","article-title":"Thalidomide: dermatological indications, mechanisms of action and side-effects","volume":"153","author":"Wu","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/2040620711413165","article-title":"The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development","volume":"2","author":"Rehman","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jaad.2015.01.002_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clim.2013.03.004","article-title":"Thalidomide attenuates excessive inflammation without interrupting lipopolysaccharide-driven inflammatory cytokine production in chronic granulomatous disease","volume":"147","author":"Kawai","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaad.2015.01.002_bib5","series-title":"Comprehensive dermatologic drug therapy","first-page":"424","article-title":"Miscellaneous systemic drugs","author":"Davis","year":"2013"},{"key":"10.1016\/j.jaad.2015.01.002_bib6","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.2174\/156802612801784443","article-title":"TNF \u03b1 signaling beholds thalidomide saga: a review of mechanistic role of TNF-\u03b1 signaling under thalidomide","volume":"12","author":"Majumder","year":"2012","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.jaad.2015.01.002_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2133\/dmpk.DMPK-12-RV-089","article-title":"Clinical evidence of pharmacokinetic changes in thalidomide therapy","volume":"28","author":"Nakamura","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jaad.2015.01.002_bib8","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1200\/JCO.2004.04.565","article-title":"Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer","volume":"22","author":"Chintagumpala","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2015.01.002_bib9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/00002018-200629040-00003","article-title":"Thalidomide use in the US: experience with pregnancy testing in the S.T.E.P.S. program","volume":"29","author":"Uhl","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2015.01.002_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbmt.2010.05.011","article-title":"Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease","volume":"17","author":"Wolff","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaad.2015.01.002_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2141.1991.tb04377.x","article-title":"Thalidomide treatment for chronic graft-versus-host disease","volume":"78","author":"Heney","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2015.01.002_bib12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM199204163261604","article-title":"Thalidomide for the treatment of chronic graft-versus-host disease","volume":"326","author":"Vogelsang","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2015.01.002_bib13","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1542\/peds.103.4.e44","article-title":"Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature","volume":"103","author":"Mehta","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2015.01.002_bib14","first-page":"937","article-title":"Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation","volume":"14","author":"Cole","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaad.2015.01.002_bib15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/sj.bmt.1701138","article-title":"The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children","volume":"21","author":"Rovelli","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaad.2015.01.002_bib16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1525-1470.2008.00643.x","article-title":"Sclerodermatous chronic graft-versus-host disease\u2013a report of four pediatric cases","volume":"25","author":"Tolland","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib17","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaad.2004.10.863","article-title":"Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide","volume":"52","author":"Letsinger","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1525-1470.1993.tb00377.x","article-title":"Recurrent giant aphthous ulcers in a child: protracted treatment with thalidomide","volume":"10","author":"Menni","year":"1993","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib19","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00006454-199605000-00019","article-title":"Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral aphthous ulcers","volume":"15","author":"DeVincenzo","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaad.2015.01.002_bib20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/adc.74.1.64","article-title":"Thalidomide treatment of mucosal ulcerations in HIV infection","volume":"74","author":"Sol\u00e8r","year":"1996","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaad.2015.01.002_bib21","first-page":"97","article-title":"Steroid-resistant idiopathic esophageal ulcer in a child with AIDS","volume":"27","author":"Jibaly","year":"1998","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jaad.2015.01.002_bib22","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/rheumatology\/40.8.933","article-title":"Beh\u00e7et's disease in UK children: clinical features and treatment including thalidomide","volume":"40","author":"Kari","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2015.01.002_bib23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ibd.20317","article-title":"Thalidomide for treatment of intestinal involvement of juvenile-onset Beh\u00e7et disease","volume":"14","author":"Yasui","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2015.01.002_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1525-1470.2001.018002143.x","article-title":"Successful thalidomide treatment of severe infantile Beh\u00e7et disease","volume":"18","author":"Brik","year":"2001","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib25","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/j.tripleo.2009.03.042","article-title":"Dyskeratosis congenita: a case report","volume":"108","author":"Abdel-Karim","year":"2009","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.jaad.2015.01.002_bib26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2340\/00015555-0997","article-title":"Efficacy of thalidomide in the treatment of prurigo nodularis","volume":"91","author":"Taefehnorooz","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2015.01.002_bib27","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1440-0960.2002.00593.x","article-title":"Thalidomide experience of a major Australian teaching hospital","volume":"43","author":"Crouch","year":"2002","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib28","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0190-9622(96)90122-X","article-title":"Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses","volume":"35","author":"Tseng","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib29","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1365-2133.2005.06492.x","article-title":"Thalidomide in the management of epidermolysis bullosa pruriginosa","volume":"152","author":"Ozanic Bulic","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib30","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1525-1470.2012.01757.x","article-title":"An incompletely penetrant novel mutation in COL7A1 causes epidermolysis bullosa pruriginosa and dominant dystrophic epidermolysis bullosa phenotypes in an extended kindred","volume":"29","author":"Yang","year":"2012","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib31","first-page":"487","article-title":"Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide","volume":"11","author":"Atra","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib32","first-page":"1429","article-title":"Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy","volume":"27","author":"Ordi-Ros","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib33","first-page":"82","article-title":"Lupus erythematosus panniculitis in children and adolescents","volume":"37","author":"Guissa","year":"2012","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.jaad.2015.01.002_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/09546630152607871","article-title":"Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus","volume":"12","author":"Thomson","year":"2001","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2015.01.002_bib35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1525-1470.2008.00838.x","article-title":"An infant with acrodermatitis continua of Hallopeau: successful treatment with thalidomide and UVB therapy","volume":"26","author":"Kiszewski","year":"2009","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/03009740410010236","article-title":"The clinical course of a child with CINCA\/NOMID syndrome improved during and after treatment with thalidomide","volume":"34","author":"Kallinich","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib37","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1525-1470.1993.tb00371.x","article-title":"Chronic bullous disease of childhood and ulcerative colitis","volume":"10","author":"Handley","year":"1993","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4103\/0378-6323.66601","article-title":"Linear IgA bullous dermatosis of childhood: response to thalidomide","volume":"76","author":"Madnani","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2015.01.002_bib39","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/j.1365-2133.2006.07464.x","article-title":"A child with laryngo-onychocutaneous syndrome partially responsive to treatment with thalidomide","volume":"155","author":"Strauss","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib40","first-page":"322","article-title":"Thalidomide-induced sensory neuropathy","volume":"32","author":"Strauss","year":"2001","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jaad.2015.01.002_bib41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MPG.0b013e318228349e","article-title":"Thalidomide use and outcomes in pediatric patients with Crohn disease\u00a0refractory to infliximab and adalimumab","volume":"54","author":"Felipez","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jaad.2015.01.002_bib42","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.2013.280777","article-title":"Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial","volume":"310","author":"Lazzerini","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2015.01.002_bib43","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1542\/peds.103.6.1295","article-title":"Thalidomide responsiveness in an infant with Beh\u00e7et's syndrome","volume":"103","author":"Shek","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2015.01.002_bib44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1590\/S1807-59322009000300008","article-title":"Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial","volume":"64","author":"Mimura","year":"2009","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.jaad.2015.01.002_bib45","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jpeds.2004.08.020","article-title":"Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study","volume":"145","author":"Lehman","year":"2004","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaad.2015.01.002_bib46","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2036.2006.03211.x","article-title":"Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results","volume":"25","author":"Lazzerini","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaad.2015.01.002_bib47","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/pbc.24794","article-title":"A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer","volume":"61","author":"Robison","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2015.01.002_bib48","first-page":"63","article-title":"Transient secondary amenorrhea in women treated by thalidomide","volume":"12","author":"Frances","year":"2002","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib49","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/MPH.0b013e3182580d6e","article-title":"Thalidomide therapy for aggressive histiocytic lesions in the pediatric population","volume":"34","author":"Bailey","year":"2012","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jaad.2015.01.002_bib50","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1002\/ibd.22845","article-title":"Amenorrhea in women treated with thalidomide: report of two cases and literature review","volume":"19","author":"Lazzerini","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2015.01.002_bib51","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1212\/WNL.62.12.2291","article-title":"Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study","volume":"62","author":"Cavaletti","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2015.01.002_bib52","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.nmd.2004.10.005","article-title":"Thalidomide neuropathy in childhood","volume":"15","author":"Fleming","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jaad.2015.01.002_bib53","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1523-1747.2002.19502.x","article-title":"Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients","volume":"119","author":"Bastuji-Garin","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2015.01.002_bib54","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.pediatrneurol.2007.11.004","article-title":"Childhood thalidomide neuropathy: a clinical and neurophysiologic study","volume":"38","author":"Priolo","year":"2008","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.jaad.2015.01.002_bib55","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/pbc.20578","article-title":"A phase II trial using thalidomide for Langerhans cell histiocytosis","volume":"48","author":"McClain","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2015.01.002_bib56","unstructured":"US Food and Drug Administration. Efficacy supplement with clinical data to support. Available from: URL: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020785s048lbl.pdf. Accessed August 31, 2014."},{"key":"10.1016\/j.jaad.2015.01.002_bib57","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1055\/s-0032-1328890","article-title":"Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the US Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR)","volume":"38","author":"Moore","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jaad.2015.01.002_bib58","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/pbc.24006","article-title":"Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors","volume":"59","author":"Peyrl","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2015.01.002_bib59","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/MPG.0b013e31829ce5cd","article-title":"Risk factors, morbidity, and treatment of thrombosis in children and\u00a0young adults with active inflammatory bowel disease","volume":"57","author":"Zitomersky","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jaad.2015.01.002_bib60","first-page":"143","article-title":"Use of thalidomide in the management of three HIV seroreactive children with Kaposi's sarcoma referred for palliative care","volume":"20","author":"Bunn","year":"2008","journal-title":"Malawi Med J"},{"key":"10.1016\/j.jaad.2015.01.002_bib61","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199705223362103","article-title":"Thalidomide\u00a0for\u00a0the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection; National Institute of Allergy and Infectious Diseases AIDS\u00a0Clinical Trials Group","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2015.01.002_bib62","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/088307380401900402","article-title":"Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study","volume":"19","author":"Schoeman","year":"2004","journal-title":"J Child Neurol"},{"key":"10.1016\/j.jaad.2015.01.002_bib63","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/pbc.21075","article-title":"Myelodysplastic syndrome with trisomy 8 associated with Beh\u00e7et syndrome: an immunologic link to a karyotypic abnormality","volume":"50","author":"Thachil","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2015.01.002_bib64","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3171\/PED\/2008\/2\/8\/125","article-title":"Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma","volume":"2","author":"Frei-Jones","year":"2008","journal-title":"J\u00a0Neurosurg Pediatr"},{"key":"10.1016\/j.jaad.2015.01.002_bib65","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s13312-013-0041-0","article-title":"Thalidomide for systemic onset\u00a0juvenile idiopathic arthritis","volume":"50","author":"Sathe","year":"2013","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.jaad.2015.01.002_bib66","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jbspin.2006.12.004","article-title":"Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis","volume":"74","author":"Garc\u00eda-Carrasco","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jaad.2015.01.002_bib67","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/art.25035","article-title":"Thalidomide dramatically improves the symptoms of early-onset sarcoidosis\/Blau syndrome: its possible action and mechanism","volume":"62","author":"Yasui","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2015.01.002_bib68","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1546-0096-8-6","article-title":"Efficacy of thalidomide in a girl with inflammatory calcinosis, a severe complication of juvenile dermatomyositis","volume":"8","author":"Miyamae","year":"2010","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jaad.2015.01.002_bib69","first-page":"176","article-title":"Penile and scrotum swelling in juvenile dermatomyositis","volume":"36","author":"Sallum","year":"2011","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.jaad.2015.01.002_bib70","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00431-008-0721-2","article-title":"IBD and IBD mimicking enterocolitis in children younger than 2 years of age","volume":"168","author":"Cannioto","year":"2009","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jaad.2015.01.002_bib71","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3748\/wjg.v17.i10.1286","article-title":"Treatment of pediatric\u00a0refractory Crohn's disease with thalidomide","volume":"17","author":"Zheng","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaad.2015.01.002_bib72","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jaci.2013.04.059","article-title":"Efficacy and safety of thalidomide in patients with inflammatory manifestations of\u00a0chronic granulomatous disease: a retrospective case series","volume":"132","author":"Noel","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2015.01.002_bib73","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/0883073809350507","article-title":"Tuberculous meningitis-related optic neuritis: recovery of vision with thalidomide in 4 consecutive cases","volume":"25","author":"Schoeman","year":"2010","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.jaad.2015.01.002_bib74","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/088307380001500801","article-title":"Adjunctive thalidomide therapy of childhood tuberculous meningitis: possible anti-inflammatory role","volume":"15","author":"Schoeman","year":"2000","journal-title":"J Child Neurol"},{"key":"10.1016\/j.jaad.2015.01.002_bib75","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/0883073808322329","article-title":"Recovery\u00a0of vision after adjuvant thalidomide in a child with tuberculous meningitis and acute lymphoblastic leukemia","volume":"24","author":"Stefan","year":"2009","journal-title":"J Child Neurol"},{"key":"10.1016\/j.jaad.2015.01.002_bib76","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.arcmed.2008.05.008","article-title":"Phase II study of metronomic chemotherapy with thalidomide, carboplatin-vincristine-fluvastatin in the treatment of brain stem tumors in children","volume":"39","author":"L\u00f3pez-Aguilar","year":"2008","journal-title":"Arch Med Res"},{"key":"10.1016\/j.jaad.2015.01.002_bib77","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1200\/JCO.2007.12.3331","article-title":"Successful antiangiogenic therapy for neuroblastoma with thalidomide","volume":"25","author":"Gesundheit","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2015.01.002_bib78","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1651-2227.2010.01961.x","article-title":"Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas","volume":"100","author":"Kivivuori","year":"2011","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jaad.2015.01.002_bib79","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/pbc.25045","article-title":"Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma","volume":"61","author":"Porkholm","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2015.01.002_bib80","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11060-010-0157-1","article-title":"A prospective study of temozolomide plus thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean Society for Pediatric Neuro-Oncology study","volume":"100","author":"Kim","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jaad.2015.01.002_bib81","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/pbc.21045","article-title":"A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies","volume":"49","author":"Gilheeney","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2015.01.002_bib82","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1212\/01.WNL.0000042321.94839.78","article-title":"Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1","volume":"60","author":"Gupta","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2015.01.002_bib83","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/pbc.22065","article-title":"Monotherapy with thalidomide for treatment of spinal cord hemangioblastomas in a patient with von Hippel-Lindau disease","volume":"53","author":"Sardi","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2015.01.002_bib84","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1007\/s11999-009-0838-2","article-title":"Kaposiform hemangioendothelioma in multiple spinal levels without skin changes","volume":"467","author":"Lisle","year":"2009","journal-title":"Clin Orthop Relat Res"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215000055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215000055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:34:03Z","timestamp":1759271643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962215000055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0190962215000055"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2015.01.002","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of thalidomide use in the pediatric population","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2015.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}